The importance of the patients' experience of RA compared with clinical measures of disease activity

Clinical and Experimental Rheumatology

Volumn 28, Issue 3 SUPPL. 59, 2010, Pages

  Taylor, Peter C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Certolizumab pegol; Health outcomes; Rheumatoid arthritis

Indexed keywords

CERTOLIZUMAB PEGOL; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR;

ANXIETY; CLINICAL DECISION MAKING; COMORBIDITY; DISEASE ACTIVITY; HEALTH SURVEY; HUMAN; JOINT STIFFNESS; JOINT SWELLING; MOTIVATION; NEUROMODULATION; OUTCOME ASSESSMENT; PERCEPTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; DISABILITY; HEALTH STATUS; HOSPITALIZATION; PATHOPHYSIOLOGY; PATIENT; PSYCHOLOGICAL ASPECT;

ARTHRITIS, RHEUMATOID; DISABILITY EVALUATION; HEALTH STATUS; HUMANS; PATIENTS; SEVERITY OF ILLNESS INDEX;

EID: 77956410442     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. KLARESKOG L, VAN DER HD, DE JAGER JP et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-81.
2. ST CLAIR EW, VAN DER HEIJDE DM, SMOLEN JS et al.: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 3432-43.
3. BREEDVELD FC, WEISMAN MH, KAVANAUGH AF et al.: The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26-37.
4. LIPSKY PE, VAN DER HEIJDE DMFM, ST CLAIR EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594-602.
5. KEYSTONE EC, KAVANAUGH AF, SHARP JT et al.: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400-11.
6. MAINI RN, BREEDVELD FC, KALDEN JR et al.: Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004; 50: 1051-65.
7. VAN DER HEIJDE D, LANDEWE R, VAN VOLLENHOVEN R, FATENEJAD S, KLARESKOG L: Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial. Ann Rheum Dis 2008; 67: 1267-70.
8. BEJARANO V, QUINN M, CONAGHAN PG et al.: Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 2008; 59: 1467-74.
9. NARANJO A, SOKKA T, DESCALZO MA et al.: Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008; 10: R30.
10. AVOUAC J, ALLANORE Y: Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs. Expert Opin Pharmacother 2008; 9: 1121-8.
11. STEINBROOK R: Saying no isn't NICE - the travails of Britain's National Institute for Health and Clinical Excellence. N Engl J Med 2008; 359: 1977-81.
12. GOSSEC L, DOUGADOS M, RINCHEVAL N et al.: The elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. Ann Rheum Dis 2008; Dec 3: [Epub ahead of print].
13. KEYSTONE E, VAN DER HEIJDE D, MASON D et al.: Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008; 58: 3319-29.
14. SMOLEN J, LANDEWE R, MEASE P et al.: Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009; 68: 797-804.
15. FLEISCHMANN R, VENCOVSKY J, VAN VOLLENHOVEN R et al.: Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009; 68: 805-11.
16. SCHIFF M, KEININGER DL, TAHARI-FITZGERALD E: Certolizumab pegol added onto methotrexate improves physical function and reduces pain in patients with rheumatoid arthritis who have an incomplete response to methotrexate. Barcelona, Spain: EULAR; June 13-16, 2007.
17. HAZES JM, TAYLOR P, STRAND V, PUCARU O, COTEUR G, MEASE P: Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol. Rheumatology 2009; Submitted.
18. KAVANAUGH A, SMOLEN J, EMERY P et al.: Certolizumab pegol with methotrexate improves home and workplace productivity and social activities in patients with active rheumatoid arthritis. Arthritis Care Res 2009; In press.
19. TAYLOR P, MANGER B, ALVARO-GRACIA J et al.: High unmet need for arthritis pain relief among rheumatoid arthritis patients despite effective treatment of synovitis. Ann Rheum Dis 2008; 67 (Suppl. II): 72.
20. TAYLOR P, MANGER B, ALVARO-GRACIA J et al.: Differences in patient and physician perceptions regarding decision-making, knowledge and emotional support in the treatment of rheumatoid arthritis (RA). Ann Rheum Dis 2008; 67 (Suppl. II): 316.